Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Elderly Patient
93%
Overall Survival
63%
Progression Free Survival
53%
Diseases
51%
Positron Emission Tomography-Computed Tomography
51%
Hodgkin's Lymphoma
46%
Chemotherapy
39%
Follicular Lymphoma
34%
Methotrexate
34%
COVID-19
34%
Cohort Analysis
34%
Chimeric Antigen Receptor T-Cell
34%
Polyethylene Terephthalate
34%
Rituximab
33%
Drug Megadose
25%
Radiation Therapy
25%
Infection
24%
Cytarabine
24%
Polatuzumab Vedotin
22%
Cyclophosphamide
22%
Splenomegaly
21%
Autologous Stem Cell Transplantation
19%
Thrombocytopenia
19%
Chemoimmunotherapy
19%
Lymphoproliferative Disease
17%
Janus Kinase 2
17%
Myeloproliferative Neoplasm
17%
Phlebothrombosis
17%
Central Nervous System Disease
17%
Prospective Study
17%
Patient with Inflammatory Bowel Disease
17%
Cytomegalovirus
17%
Cell Transplantation
17%
Hematologic Malignancy
17%
Cannabis Use
17%
Gastrointestinal Tract
17%
Aggressive Lymphoma
17%
Breast Cancer Screening
17%
Mantle Cell Lymphoma
17%
Chimeric Antigen Receptor T-Cell Immunotherapy
17%
Computer Assisted Tomography
17%
Patient Experience
17%
Medical Cannabis
17%
Splenectomy
17%
Hairy Cell Leukemia
17%
Personal Experience
17%
Chimeric Antigen Receptor
17%
Pancytopenia
17%
Metastatic Colorectal Cancer
17%
Keyphrases
Elderly Patients
85%
Lymphoma Patients
61%
Diffuse Large B-cell Lymphoma (DLBCL)
54%
Overall Survival
51%
High-dose Methotrexate (HD-MTX)
51%
Retrospective Analysis
51%
Single Center
36%
Rituximab
36%
Chimeric Antigen Receptor T Cells (CAR-T)
34%
Hodgkin Lymphoma
34%
Primary Central Nervous System Lymphoma (PCNSL)
34%
Acute Myeloid Leukemia
34%
Working Diagnosis
34%
Chemotherapy
30%
Progression-free Survival
29%
Cytarabine
25%
Radiotherapy
25%
Positron Emission Tomography/computed Tomography (PET/CT)
22%
Follicular Lymphoma
21%
Autologous Stem Cell Transplantation (auto-SCT)
21%
Blood Count
20%
Thrombocytopenia
20%
Large B-cell Lymphoma
20%
Online Treatment
19%
Splenomegaly
19%
Chemoimmunotherapy
18%
Median Progression-free Survival
17%
Hodgkin
17%
COVID-19
17%
Polatuzumab
17%
Israeli
17%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
17%
Occult
17%
Abdominal
17%
Janus Kinase 2 (JAK2)
17%
Venous Thrombosis
17%
Myeloproliferative Neoplasms
17%
Normal Blood
17%
Pancytopenia
17%
Relapsed/refractory
17%
Predictive Value
17%
Patient Experience
17%
Matched Cohort Analysis
17%
Cytogenetic Risk
17%
Catheter Removal
17%
Splenectomy
17%
Hairy Cell Leukemia
17%
Reduced Dose
17%
Central Nervous System Diseases
17%
Cytomegalovirus
17%